WuXi Biologics, part of WuXi AppTec, a contract service provider, plans to invest EUR 325 million ($392 million) in a new biologics drug-substance manufacturing facility in Mullagharlin, Dundalk, County Louth, Ireland.

The company says the facility will use multiple single-use bioreactors for commercial biomanufacturing and is designed to be able to run continuous bioprocessing. A total of 48,000 liters of fed-batch bioreactor capacity and 6,000 liters of perfusion bioreactor capacity will be installed.

The manufacturing site will be on a 26-hectare campus and is WuXi Biologics’ first site outside of China. It is supported by the Irish Government through IDA Ireland, an economic development body for Ireland. This investment is expected to create over 400 skilled jobs over five years as well as add approximately 700 construction jobs.

Source: Wuxi Biologics